Search

Author/Creator Papp, Kim A

1. Bimekizumab versus ustekinumab for the treatment of moderate to severe plaque psoriasis (BE VIVID): efficacy and safety from a 52-week, multicentre, double-blind, active comparator and placebo controlled phase 3 trial. Issue 10273 (6th February 2021)

Authors:
Reich, Kristian; Papp, Kim A; Blauvelt, Andrew; Langley, Richard G; Armstrong, April; Warren, Richard B; Gordon, Kenneth B; Merola, Joseph F; Okubo, Yukari; Madden, Cynthia; Wang, Maggie; Cioffi, Christopher; Vanvoorden, Veerle; Lebwohl, Mark
Journal:
Lancet
Issue:
Volume 397:Issue 10273(2021)
Page Start:
487
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

2. Corrigendum to: Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. (22nd February 2021)

Authors:
Genovese, Mark C; Mysler, Eduardo; Tomita, Tetsuya; Papp, Kim A; Salvarani, Carlo; Schwartzman, Sergio; Gallo, Gaia; Patel, Himanshu; Lisse, Jeffrey R; Kronbergs, Andris; Leage, Soyi Liu; Adams, David H; Xu, Wen; Marzo-Ortega, Helena; Lebwohl, Mark G
Journal:
Rheumatology
Issue:
Volume 60:Number 11(2021)
Page Start:
5485
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

3. Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials. Issue 10148 (25th August 2018)

Authors:
Gordon, Kenneth B; Strober, Bruce; Lebwohl, Mark; Augustin, Matthias; Blauvelt, Andrew; Poulin, Yves; Papp, Kim A; Sofen, Howard; Puig, Lluís; Foley, Peter; Ohtsuki, Mamitaro; Flack, Mary; Geng, Ziqian; Gu, Yihua; Valdes, Joaquin M; Thompson, Elizabeth H Z; Bachelez, Hervé
Journal:
Lancet
Issue:
Volume 392:Issue 10148(2018)
Page Start:
650
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

7. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Issue 10086 (10th June 2017)

Authors:
Blauvelt, Andrew; de Bruin-Weller, Marjolein; Gooderham, Melinda; Cather, Jennifer C; Weisman, Jamie; Pariser, David; Simpson, Eric L; Papp, Kim A; Hong, H Chih-Ho; Rubel, Diana; Foley, Peter; Prens, Errol; Griffiths, Christopher E M; Etoh, Takafumi; Pinto, Pedro Herranz; Pujol, Ramon M; Szepieto...
Journal:
Lancet
Issue:
Volume 389:Issue 10086(2017)
Page Start:
2287
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

9. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Issue 10290 (5th June 2021)

Authors:
Guttman-Yassky, Emma; Teixeira, Henrique D; Simpson, Eric L; Papp, Kim A; Pangan, Aileen L; Blauvelt, Andrew; Thaçi, Diamant; Chu, Chia-Yu; Hong, H Chih-ho; Katoh, Norito; Paller, Amy S; Calimlim, Brian; Gu, Yihua; Hu, Xiaofei; Liu, Meng; Yang, Yang; Liu, John; Tenorio, Allan R; Chu, Alvina D; Ir...
Journal:
Lancet
Issue:
Volume 397:Issue 10290(2021)
Page Start:
2151
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

10. Safety of ixekizumab in adult patients with plaque psoriasis, psoriatic arthritis and axial spondyloarthritis: data from 21 clinical trials. (25th May 2020)

Authors:
Genovese, Mark C; Mysler, Eduardo; Tomita, Tetsuya; Papp, Kim A; Salvarani, Carlo; Schwartzman, Sergio; Gallo, Gaia; Patel, Himanshu; Lisse, Jeffrey R; Kronbergs, Andris; Leage, Soyi Liu; Adams, David H; Xu, Wen; Marzo-Ortega, Helena; Lebwohl, Mark G
Journal:
Rheumatology
Issue:
Volume 59:Number 12(2020)
Page Start:
3834
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗